Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and OEM. It offers electrosurgical generators based on its Helium Plasma Technology for cutting, coagulation, and ablation of soft tissue. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market that allows surgeons to operate with precision and eliminate unintended tissue trauma. It also develops, manufactures, and sells energy generators, disposable hand piece subassemblies, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
IPO Year:
Exchange: NASDAQ
Website: apyxmedical.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/17/2024 | Neutral | BTIG Research | |
| 7/14/2023 | $8.00 | Overweight | Stephens |
| 5/20/2022 | $12.00 | Buy | Lake Street |
| 8/13/2021 | $12.00 → $14.00 | Market Outperform | JMP Securities |
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
3 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
CLEARWATER, Fla., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that Charles Goodwin, President and CEO and Matt Hill, CFO will be attending the following upcoming conference: Event: 15th Annual Craig-Hallum Alpha Select ConferenceDate: November 19, 2024Location: Sheraton NY Times Square Hotel, New York, NYFormat: 1x1 Meetings To request a meeting with Apyx, investors should contact their Craig Hallum representative. About Apyx Medical Corporation: Apyx Medical Corporation is an advanced energy
CLEARWATER, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced it has entered into a definitive purchase agreement with Nantahala Capital for the purchase and sale in a registered direct offering of 3,000,000 shares of the Company's common stock at a purchase price of $1.18 per share and pre-funded warrants to purchase up to 2,934,690 shares of the Company's common stock at a purchase price of $1.179 per pre-funded warrant (which represents the per share offering price for common stock less the
Strengthened balance sheet with a common stock registered direct offering with gross proceeds of approximately $7.0 million; and amended revenue covenants for the Company's credit agreement with PerceptiveAnnounces cost savings restructuring program to better focus, optimize and streamline operations, including a nearly 25% reduction in U.S. workforce Announces 9% overall growth in single-use handpiece revenue and 15% growth in the U.S.Management to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platfor
CLEARWATER, Fla., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that financial results for the third quarter of fiscal year 2024 will be released before the market opens on Friday, November 8th. Management will host a conference call at 8:00 a.m. Eastern Time on November 8th to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 877-407-9039 (or 201-689-8470 for international callers) and provide access code 13
Independent survey reveals Renuvion is #1 trusted body contouring technology* with plastic and cosmetic surgeons. CLEARWATER, Fla., Aug. 13, 2024 /PRNewswire/ -- Apyx® Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), a leader in advanced energy technology and the manufacturer of Renuvion®, today announced that doctors named Renuvion as the #1 trusted body contouring technology in an independent survey by Wakefield Research.** This recognition underscores the effectiveness of Renuvion's novel technology that targets loose skin at the source, offering unparalleled results for body contouring procedures.
Demonstrates a statistically significant reduction in adverse events associated with the use of Renuvion following liposuction or body contouring, compared to the competing technology Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced the publication of a peer-reviewed article in the journal, Plastic and Reconstructive Surgery—Global Open, featuring the results of study which compared the use of Renuvion's Helium Plasma Technology to InMode's Bipolar RF System ("Bipolar RF") following liposuction or body contouring procedures. In thi
Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported financial results for its second quarter ended June 30, 2024; and updated its financial expectations for the full year ending December 31, 2024. Second Quarter 2024 Financial Summary: Total revenue of $12.1 million, a decrease of 10% year-over-year. Advanced Energy revenue of $9.8 million, a decrease of 17% year-over-year. OEM revenue of $2.4 million, an increase of 29% year-over-year. Net loss attributable to stockholders of $6.6 million, an increase of $5.6 million, or 5
Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that financial results for the second quarter of fiscal year 2024 will be released after the market closes on Thursday, August 8th. Management will host a conference call at 5:00 p.m. Eastern Time on August 8th to discuss the results of the quarter, and to host a question and answer session. To listen to the call by phone, interested parties may dial 888-645-4404 (or 862-298-0702 for international callers) and provide access code 13747529. Participants should ask for the Apyx Medical Corporation Call.
Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its first quarter ended March 31, 2024; and reaffirmed its financial expectations for the full year ending December 31, 2024. First Quarter 2024 Financial Summary: Total revenue of $10.2 million, a decrease of 16% year-over-year. Advanced Energy revenue of $7.5 million, a decrease of 23% year-over-year. OEM revenue of $2.8 million, an increase of 14% year-over-year. Net loss attributable to stockholders of $7.6 million, an increase of $4.1 million, or 118%, ye
Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
4 - Apyx Medical Corp (0000719135) (Issuer)
BTIG Research initiated coverage of Apyx Medical with a rating of Neutral
Stephens initiated coverage of Apyx Medical with a rating of Overweight and set a new price target of $8.00
Lake Street initiated coverage of Apyx Medical with a rating of Buy and set a new price target of $12.00
JMP Securities reiterated coverage of Apyx Medical with a rating of Market Outperform and set a new price target of $14.00 from $12.00 previously
Piper Sandler reiterated coverage of Apyx Medical with a rating of Overweight and set a new price target of $12.00 from $8.00 previously
CLEARWATER, Fla., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that financial results for the third quarter of fiscal year 2024 will be released before the market opens on Friday, November 8th. Management will host a conference call at 8:00 a.m. Eastern Time on November 8th to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 877-407-9039 (or 201-689-8470 for international callers) and provide access code 13
Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported financial results for its second quarter ended June 30, 2024; and updated its financial expectations for the full year ending December 31, 2024. Second Quarter 2024 Financial Summary: Total revenue of $12.1 million, a decrease of 10% year-over-year. Advanced Energy revenue of $9.8 million, a decrease of 17% year-over-year. OEM revenue of $2.4 million, an increase of 29% year-over-year. Net loss attributable to stockholders of $6.6 million, an increase of $5.6 million, or 5
Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that financial results for the second quarter of fiscal year 2024 will be released after the market closes on Thursday, August 8th. Management will host a conference call at 5:00 p.m. Eastern Time on August 8th to discuss the results of the quarter, and to host a question and answer session. To listen to the call by phone, interested parties may dial 888-645-4404 (or 862-298-0702 for international callers) and provide access code 13747529. Participants should ask for the Apyx Medical Corporation Call.
Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its first quarter ended March 31, 2024; and reaffirmed its financial expectations for the full year ending December 31, 2024. First Quarter 2024 Financial Summary: Total revenue of $10.2 million, a decrease of 16% year-over-year. Advanced Energy revenue of $7.5 million, a decrease of 23% year-over-year. OEM revenue of $2.8 million, an increase of 14% year-over-year. Net loss attributable to stockholders of $7.6 million, an increase of $4.1 million, or 118%, ye
Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2024 will be released before the market opens on Thursday, May 9th. Management will host a conference call at 8:00 a.m. Eastern Time on May 9th to discuss the results of the quarter, and to host a question and answer session. To listen to the call by phone, interested parties may dial 888-645-4404 (or 862-298-0702 for international callers) and provide access code 13745889. Participants should ask for the Apyx Medical Corporation Call. A live webcast
Advanced Energy Sales increased 15% year-over-year and 23% quarter-over-quarter in the fourth quarter; increased 18% year-over-year in 2023 Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its fourth quarter and full year ended December 31, 2023, and introduced financial expectations for the full year ending December 31, 2024. Fourth Quarter 2023 Financial Summary: Total revenue of $14.7 million, an increase of 16% year-over-year. Advanced Energy revenue of $12.1 million, an increase of 15% year-over-year. OEM r
Apyx® Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the fourth quarter and fiscal year 2023 will be released before the market opens on Thursday, March 21st. Management will host a conference call at 8:00 a.m. Eastern Time on March 21st to discuss the results of the quarter and year, and to host a question and answer session. To listen to the call by phone, interested parties may dial 877-407-8289 (or 201-689-8341 for international callers) and provide access code 13744178. Participants should ask for the Apyx Medical Corporation Cal
Advanced Energy Sales increased 39% year-over-year in Q3 Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its third quarter ended September 30, 2023, and updated its financial expectations for the full year ending December 31, 2023. Third Quarter 2023 Financial Summary: Total revenue of $12.0 million, up 31% year-over-year. Advanced Energy revenue of $9.8 million, up 39% year-over-year. OEM revenue of $2.1 million, up 5% year-over-year. Net loss attributable to stockholders of $4.6 million, down $1.1 million, or 20%, year
Apyx® Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the third quarter of fiscal year 2023 will be released before the market opens on Thursday, November 9th. Management will host a conference call at 8:00 a.m. Eastern Time on November 9th to discuss the results of the quarter, and to host a question and answer session. To listen to the call by phone, interested parties may dial 877-407-8289 (or 201-689-8341 for international callers) and provide access code 13741467. Participants should ask for the Apyx Medical Corporation Call. A li
Advanced Energy Sales increased 40% year-over-year in Q2 Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its second quarter ended June 30, 2023, and reaffirms financial expectations for the full year ending December 31, 2023. Second Quarter 2023 Financial Summary: Total revenue of $13.6 million, up 32% year-over-year. Advanced Energy revenue of $11.7 million, up 40% year-over-year. OEM revenue of $1.8 million, down 4% year-over-year. Net loss attributable to stockholders of $1.0 million, down $4.4 million, or 82%, year-o
10-Q - Apyx Medical Corp (0000719135) (Filer)
424B5 - Apyx Medical Corp (0000719135) (Filer)
8-K - Apyx Medical Corp (0000719135) (Filer)
8-K - Apyx Medical Corp (0000719135) (Filer)
10-Q - Apyx Medical Corp (0000719135) (Filer)
8-K - Apyx Medical Corp (0000719135) (Filer)
DEF 14A - Apyx Medical Corp (0000719135) (Filer)
SD - Apyx Medical Corp (0000719135) (Filer)
10-Q - Apyx Medical Corp (0000719135) (Filer)
8-K - Apyx Medical Corp (0000719135) (Filer)
Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead
Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023. "Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies," said Charlie Goodwin, President and
NORTH BILLERICA, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("the Company") (NASDAQ:LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus' Board of Directors ("Board"), effective immediately. As an independent director, Ms. Baylor-Henry will serve as a member of the Board's Compensation Committee and the Science and Technology Committee. Following the appointment of Ms. Baylor-Henry, the Board will be comprised of nine directors, eight of whom are independent. "We are pleased to welcome Minnie Baylor-Henry, a highly respected authority in FDA law an
Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, announced today that the Company has appointed Wendy Levine to the Board of Directors, effective August 25, 2021. Ms. Levine will serve as a Director and member of the Regulatory Compliance Committee. "I am pleased to welcome Ms. Levine to our Board and look forward to leveraging her 25 years of healthcare marketing and advertising experience across the pharmaceutical, biotech, medical device and vaccine sectors," said Charlie Goodwin, Chief
SC 13G - Apyx Medical Corp (0000719135) (Subject)
SC 13G/A - Apyx Medical Corp (0000719135) (Subject)
SC 13D/A - Apyx Medical Corp (0000719135) (Subject)
SC 13D - Apyx Medical Corp (0000719135) (Subject)
SC 13D - Apyx Medical Corp (0000719135) (Subject)
SC 13G/A - Apyx Medical Corp (0000719135) (Subject)
SC 13G/A - Apyx Medical Corp (0000719135) (Subject)
SC 13G/A - Apyx Medical Corp (0000719135) (Subject)
SC 13G/A - Apyx Medical Corp (0000719135) (Subject)
SC 13G/A - Apyx Medical Corp (0000719135) (Subject)
Apyx® Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the launch of the "Renewing Lives" campaign, a nationwide, life-changing give-back program that will provide Renuvion treatments to people who can most benefit from this advanced medical technology. Renuvion is the first and only body contouring technology that empowers consumers to feel and look their best from the inside out by targeting loose skin directly at the source. As the only device that is FDA-cleared for contracting subcutaneous tissue, Renuvion provides people with a proven solu
Gainers Longeveron (NASDAQ:LGVN) stock rose 30.9% to $2.37 during Thursday's pre-market session. The company's market cap stands at $15.0 million. JanOne (NASDAQ:JAN) stock rose 26.07% to $3.24. The company's market cap stands at $37.8 million. Bionomics (NASDAQ:BNOX) shares increased by 21.62% to $0.85. The market value of their outstanding shares is at $9.0 million. BioRestorative Therapies (NASDAQ:BRTX) shares rose 20.74% to $1.63. The company's market cap stands at $11.0 million. Holdco Nuvo Group DG (NASDAQ:NUVO) stock rose 20.22% to $1.84. The company's market cap stands at $61.2 million. Vivani Medical (NASDAQ:VANI) stock rose 15.9% to $1.89. The market value of their outstandin
Apyx Medical (NASDAQ:APYX) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.21) by 4.76 percent. This is a 120 percent decrease over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $10.24 million which beat the analyst consensus estimate of $9.53 million by 7.49 percent. This is a 15.63 percent decrease over sales of $12.14 million the same period last year.
Gainers Jaguar Health (NASDAQ:JAGX) shares rose 25.3% to $0.11 during Tuesday's after-market session. The company's market cap stands at $31.1 million. aTyr Pharma (NASDAQ:LIFE) shares rose 10.45% to $1.9. The company's market cap stands at $128.7 million. Corvus Pharma (NASDAQ:CRVS) shares increased by 7.36% to $1.75. The market value of their outstanding shares is at $85.8 million. ImmuCell (NASDAQ:ICCC) shares increased by 7.27% to $5.6. The market value of their outstanding shares is at $43.4 million. Avenue Therapeutics (NASDAQ:ATXI) shares moved upwards by 6.46% to $0.16. The company's market cap stands at $6.9 million. Xilio Therapeutics (NASDAQ:XLO) shares increased by 5.34% to
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 300 points on Thursday. The Dow traded up 0.77% to 39,814.95 while the NASDAQ rose 0.25% to 16,410.54. The S&P 500 also rose, gaining, 0.38% to 5,244.72. Check This Out: Micron, Accenture And 3 Stocks To Watch Heading Into Thursday Leading and Lagging Sectors Industrials shares jumped by 1% on Thursday. In trading on Thursday, materials shares rose by just 0.1%. Top Headline Shares of Accenture Plc (NYSE:ACN) dipped around 9% on Thursday after the company reported results for its fiscal second quarter. Accenture reported second-quarter fiscal 2024 sales of $15.80 billion compar
Shares of FactSet Research Systems Inc. (NYSE:FDS) fell sharply during Thursday’s session after the company reported worse-than-expected second-quarter revenue and issued FY24 guidance. FactSet Research posted adjusted earnings of $4.22 per share, beating market estimates of $3.88 per share. The company’s quarterly sales came in at $545.95 million, missing expectations of $546.80 million, according to data from Benzinga Pro. FactSet Research shares dipped 5.2% to $462.36 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Yield10 Bioscience, Inc. (NASDAQ:YTEN) shares jumped 136.7% to $0.5751 after the company announced that the USDA-APHIS Biotechnology
Gainers Yield10 Bioscience (NASDAQ:YTEN) shares moved upwards by 71.5% to $0.42 during Thursday's regular session. The market value of their outstanding shares is at $4.9 million. Monogram Orthopaedics (NASDAQ:MGRM) stock rose 28.74% to $2.15. The market value of their outstanding shares is at $68.0 million. As per the press release, Q4 earnings came out 4 days ago. X4 Pharmaceuticals (NASDAQ:XFOR) stock increased by 21.61% to $1.24. The market value of their outstanding shares is at $207.5 million. As per the news, the Q4 earnings report came out today. Eiger BioPharmaceuticals (NASDAQ:EIGR) shares rose 17.78% to $6.33. The market value of their outstanding shares is at $9.3 million. C
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday. The Dow traded up 0.84% to 39,844.27 while the NASDAQ rose 0.61% to 16,469.28. The S&P 500 also rose, gaining, 0.56% to 5,254.11. Check This Out: Micron, Accenture And 3 Stocks To Watch Heading Into Thursday Leading and Lagging Sectors Industrials shares jumped by 1% on Thursday. In trading on Thursday, materials shares rose by just 0.1%. Top Headline Micron Technology, Inc. (NASDAQ:MU) reported upbeat results for its second quarter and issued strong third-quarter guidance on Wednesday. Micron reported first-quarter revenue of $5.82 billion, which beat the c